Publication

Article

BioPharm International

BioPharm International-04-01-2002
Volume15
Issue 4

Guest Editorial: The Protein Production Challenge

Author(s):

Roland Andersson,Richard Mynahan

by Roland Andersson and Richard Mynahan, Strategic Decisions Group Protect your revenues and profits from manufacturing scarcity.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue
Analytical Advances: Paperless or Less Paper?
Outsourcing Outlook: Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives
Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning
Beyond QSIT
Determining Protein Concentration, Part 1: Methodology
Guest Editorial: The Protein Production Challenge

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Human papillomavirus infection. Virus. HPV is the most common sexually transmitted infection globally. HPV infection is caused by human papillomavirus, a DNA virus from the papillomavirus family, 3d | Image Credit: © Naeblys - stock.adobe.com
August 16th 2025

FDA Approves Precigen’s Immunotherapy to Treat Recurrent Respiratory Papillomatosis

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 16th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Warsaw, Poland. 31 July 2024. Wola business district in the city center with office centers and modern buildings. Urban landscape. Company signboard Sanofi. | Image Credit: © Grand Warszawski - stock.adobe.com
August 16th 2025

MHRA Approves Sanofi’s Teplizumab to Delay Onset of Stage III T1D

Patrick Lavery
Mastering Antibody-Drug Conjugates
August 16th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Site Logo
August 16th 2025

Bill Hartzell, SVP, Manufacturing and Bioservices, on Emergent’s Unique Strategic Manufacturing Partnerships and the Storied History of Our Winnipeg Site

Emergent
Site Logo
August 16th 2025

A Strategic Manufacturing Partner

Emergent
© 2025 MJH Life Sciences

All rights reserved.